The PD-1 and PDL1 inhibitors/ immune checkpoint inhibitors market size has shown substantial growth, predicted to increase from $45.8 billion in 2024 to $53.15 billion in 2025, at a compound annual growth rate (CAGR) of 16.0%. This growth can be attributed to advancements in immunotherapy, increased clinical success and approvals, rising cancer incidence, and a shift in the cancer treatment paradigm. Additionally, investment in research and collaborations have contributed significantly to the market growth in the historic period.
The market size is expected to continue its rapid growth trajectory in the next few years, forecasted to reach $91.97 billion in 2029, expanding at a CAGR of 14.7%. Key factors like expanding indications, biomarker research, personalized medicine, clinical trials, and research collaborations, along with global healthcare infrastructure development, will drive the growth in the forecast period.
Get Your Free Sample of The Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=10788&type=smp
What Factors Are Driving the PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Growth?
The surge in cancer prevalence is a significant driver of the PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market. Cancer develops when cells grow uncontrollably and spread to other body parts. PD-1 and PD-L1 inhibitors, as part of immunotherapy, combat cancer by invigorating the body’s immune system to fight the cancer cells. Hence, the increase in cancer prevalence contributes to the market’s growth. In October 2023, according to the European Union Science Hub, the number of new cancer cases rose by 2.3% in the two years leading to 2022, amounting to 2.74 million. Consequently, such a rise in the prevalence of cancer cases will fuel the growth of the PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market.
Which Segments Are Covered in the PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Report?
1) By Product: Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab
2) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies
3) By Application: Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Colorectal Cancer, Other Applications
4) By End-Users: Hospitals, Specialty Clinics, Academic and Research Institutions
Order your report now for swift delivery:
https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report
Who Are The Key Players In The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market?
Major companies operating in the PD-1 and PDL1 inhibitors/ immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck and Company, F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., Gilead Sciences Inc., AstraZeneca plc, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, and Regeneron Pharmaceuticals Inc. Other significant operators are BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd., Akeso Inc., Alphamab Oncology, Eli Lilly and Company, Boehringer Ingelheim, Xencor Inc., Taiga Biotechnologies Inc., Jiangsu Alphamab Biopharmaceuticals Co. Ltd, Dr. Reddy’s Laboratories Ltd., Laekna Therapeutics, Genentech Inc., Tracon Pharmaceuticals Inc., Celgene, Hangzhou Sumgen Co. Ltd, Agenus Inc., BioNTech SE, Celldex Therapeutics Inc., CytomX Therapeutics Inc.
What Are the Emerging Trends in the PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market?
Product innovation is trending in the PD-1 and PDL1 Inhibitors/ immune checkpoint inhibitors market. Major market players are striving to develop innovative products to consolidate their market position. For instance, in March 2022, Bristol-Myers Squibb, a US-based pharmaceutical company, gained FDA approval for its product, Opdualag, a fixed-dose combination of nivolumab (Opdivo) and relatlimab, a LAG-3 inhibitor. This is the first LAG-3 inhibitor approved by the US Food and Drug Administration (FDA) for treating metastatic melanoma patients. The combination aims to enhance the immune response against cancer cells.
Which Region Leads the PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market?
North America was the largest region in the PD-1 and PDL1 inhibitors market in 2024. The regions covered in the PD-1 and PDL1 inhibitors/ immune checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
What Will The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Report 2025 Offer?
PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors are types of immunotherapy drugs used in cancer treatment. They work by targeting the immune system to help recognize and attack cancer cells. It is commonly used in the treatment of various cancer diseases. The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market research report from The Business Research Company provides global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Purchase the exclusive report now to unlock valuable market insights: https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10788
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
